Sistemic Overview
- Year Founded
-
2007

- Status
-
Private
- Employees
-
7

- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$652K
- Investors
-
5
Sistemic General Information
Description
Developer of microRNA analysis technology intended to offer products for the bioprocessing, cell therapy and drug discovery and development markets. The company focuses on the analysis of the information content of microRNA and other non-coding RNAs for applications in the development of cell therapies and drug repositioning, enabling healthcare professionals to easily develop cell therapies and drug repositioning without any hassle.
Contact Information
Website
www.sistemic.co.ukCorporate Office
- 2317 Maryhill Road
- Block 3, Unit 3
- Glasgow G20 0SP
- Scotland, United Kingdom
Corporate Office
- 2317 Maryhill Road
- Block 3, Unit 3
- Glasgow G20 0SP
- Scotland, United Kingdom
Sistemic Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
8. Later Stage VC | 11-Jan-2018 | $652K | Completed | Generating Revenue | ||
7. Grant | 22-Jun-2017 | Completed | Generating Revenue | |||
6. Later Stage VC | 26-Jan-2015 | Completed | Generating Revenue | |||
5. Later Stage VC | 01-Apr-2014 | Completed | Generating Revenue | |||
4. Later Stage VC | 18-Nov-2013 | Completed | Generating Revenue | |||
3. Later Stage VC | 28-Sep-2012 | Completed | Generating Revenue | |||
2. Early Stage VC | 07-Sep-2011 | $204K | $1.24M | Completed | Generating Revenue | |
1. Early Stage VC (Series A) | 17-Mar-2010 | $1.04M | $1.04M | Completed | Generating Revenue |
Sistemic Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Ordinary | ||||||||
Ordinary | ||||||||
Ordinary | ||||||||
Ordinary | ||||||||
Ordinary | 106,600 | $0.000135 | $0.4 | $0.4 | 1x | $0.4 | 6.87% | |
Series A | 133,200 | $0.000135 | $3.23 | $3.23 | 1x | $3.23 | 8.58% |
Sistemic Patents
Sistemic Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
GB-201809336-D0 | Cell contamination assay | Inactive | 06-Jun-2018 | ||
GB-201809338-D0 | Cell contamination assay | Inactive | 06-Jun-2018 | ||
GB-201809337-D0 | Cell contamination assay | Inactive | 06-Jun-2018 | ||
GB-201809238-D0 | Call contamination assay | Inactive | 05-Jun-2018 | ||
GB-201801036-D0 | Cell contamination assay | Inactive | 22-Jan-2018 |
Sistemic Signals
Sistemic Investors (5)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
TRICAPITAL Angel Investors | Angel Group | Minority | ||
Innovate UK | Government | |||
London & Scottish Investment Partners | Angel Group | Minority | ||
ChimaeraBio | Corporation | Minority | ||
Scottish Enterprise | Government | Minority |
Sistemic FAQs
-
When was Sistemic founded?
Sistemic was founded in 2007.
-
Where is Sistemic headquartered?
Sistemic is headquartered in Glasgow, United Kingdom.
-
What is the size of Sistemic?
Sistemic has 7 total employees.
-
What industry is Sistemic in?
Sistemic’s primary industry is Discovery Tools (Healthcare).
-
Is Sistemic a private or public company?
Sistemic is a Private company.
-
What is the current valuation of Sistemic?
The current valuation of Sistemic is
. -
What is Sistemic’s current revenue?
The current revenue for Sistemic is
. -
How much funding has Sistemic raised over time?
Sistemic has raised $3.39M.
-
Who are Sistemic’s investors?
TRICAPITAL Angel Investors, Innovate UK, London & Scottish Investment Partners, ChimaeraBio, and Scottish Enterprise have invested in Sistemic.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »